tiprankstipranks
Trending News
More News >
NervGen Pharma (NGENF)
OTHER OTC:NGENF

NervGen Pharma (NGENF) AI Stock Analysis

Compare
57 Followers

Top Page

NervGen Pharma (NGENF) vs. SPDR S&P 500 ETF (SPY)

NervGen Pharma Business Overview & Revenue Model

Company DescriptionNervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
How the Company Makes Money

NervGen Pharma Financial Statement Overview

Summary
NervGen Pharma is facing typical financial challenges of a biotech in the R&D phase, with consistent losses and cash burn. While there's a strong cash position from recent financing, the lack of revenue and high expenses pose significant financial risks. An improvement in equity position does slightly enhance stability, but the overall financial health remains weak until revenue opportunities are realized.
Income Statement
15
Very Negative
NervGen Pharma shows a consistent lack of revenue generation, which is typical for early-stage biotechnology firms focusing on R&D. The company continues to record negative EBIT and EBITDA margins due to high operating expenses with no offsetting revenue. Net income remains negative, reflecting ongoing development costs without commercialized products.
Balance Sheet
30
Negative
The company's balance sheet reflects high liabilities compared to equity, resulting in a negative equity position in the previous year. However, this has improved to a positive, albeit low, equity in the TTM period. The debt-to-equity ratio and equity ratio indicate a risky capital structure, but the cash position is relatively strong due to recent financing activities.
Cash Flow
40
Negative
Despite negative operating cash flows, common in biotech development phases, NervGen Pharma has managed to maintain cash reserves through significant financing activities. However, the free cash flow remains negative, indicating ongoing cash consumption without revenue generation.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
-83.80K-145.00K-115.11K-42.63K-39.65K
EBIT
-24.93M-17.78M-22.82M-12.87M-11.19M
EBITDA
-23.92M-17.72M-20.09M-12.77M-11.16M
Net Income Common Stockholders
-24.01M-22.38M-18.11M-12.64M-11.18M
Balance SheetCash, Cash Equivalents and Short-Term Investments
17.36M11.66M22.45M16.93M5.60M
Total Assets
19.49M13.24M23.88M17.90M6.68M
Total Debt
105.60K197.19K283.45K0.000.00
Net Debt
-17.16M-11.46M-22.17M-16.93M-5.60M
Total Liabilities
16.91M15.25M10.41M1.08M755.07K
Stockholders Equity
2.58M-2.01M13.46M16.82M5.92M
Cash FlowFree Cash Flow
-16.84M-11.44M-17.81M-8.31M-6.31M
Operating Cash Flow
-16.84M-11.30M-17.78M-8.27M-6.31M
Investing Cash Flow
58.87K-138.85K-21.11K-45.09K-3.42K
Financing Cash Flow
22.70M766.28K22.64M19.61M7.85M

NervGen Pharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$177.29M-248.14%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
$73.38M-64.18%
26
Underperform
C$122.59M90.17%-78.59%
$237.76M
48
Neutral
C$271.08M-11.21%86.45%
45
Neutral
C$193.35M-108.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NGENF
NervGen Pharma
2.42
0.72
42.35%
MSCLF
Satellos Bioscience
0.41
<0.01
2.50%
TSE:ARCH
Arch Biopartners
1.86
0.11
6.29%
FENC
Fennec Pharmaceuticals
8.43
1.33
18.73%
TSE:DRUG
Bright Minds Biosciences
38.27
36.78
2468.46%
TSE:EPRX
Eupraxia Pharmaceuticals
5.31
1.63
44.29%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.